Study Summary
This trial uses DECT to image patients with solid organ cancer that has spread to the brain. DECT may help find and diagnose tumor cells and find out how far the tumor cells have spread in the brain.
Eligible Conditions
- Cancer
- Brain Metastasis
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 0 Secondary · Reporting Duration: Up to 2 years
Up to 2 years
Accuracy of CT
Best diagnostic performance of computed tomography (CT) reconstruction parameters
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
Diagnostic (DECT)
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Dual-Energy Computed Tomography · No Placebo Group · N/A
Diagnostic (DECT)
Procedure
Experimental Group · 1 Intervention: Dual-Energy Computed Tomography · Intervention Types: ProcedureTrial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 2 years
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,085 Previous Clinical Trials
41,141,461 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
2,805 Previous Clinical Trials
1,790,329 Total Patients Enrolled
Jason M JohnsonPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
178 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:MRI of the brain with contrast, positive for two or more metastatic lesions.
You are planned to have stereotactic radiosurgery.
One lesion with a single greatest diameter on contrast-enhanced MRI of 1 cm or greater.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments